50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,719.04 (+1.97%)
DOW   29,683.74 (+1.88%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
S&P 500   3,719.04 (+1.97%)
DOW   29,683.74 (+1.88%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
S&P 500   3,719.04 (+1.97%)
DOW   29,683.74 (+1.88%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
S&P 500   3,719.04 (+1.97%)
DOW   29,683.74 (+1.88%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)

Plus Therapeutics - PSTV Stock Forecast, Price & News

$0.50
+0.02 (+4.21%)
(As of 09/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.45
$0.53
50-Day Range
$0.47
$1.00
52-Week Range
$0.39
$2.16
Volume
449,136 shs
Average Volume
2.58 million shs
Market Capitalization
$11.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.50

Plus Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
607.1% Upside
$3.50 Price Target
Short Interest
Healthy
0.64% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.63mentions of Plus Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.83) to ($0.45) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars

Medical Sector

330th out of 1,096 stocks

Surgical & Medical Instruments Industry

41st out of 108 stocks

PSTV stock logo

About Plus Therapeutics (NASDAQ:PSTV) Stock

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Receive PSTV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Plus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PSTV Stock News Headlines

Why Are Plus Therapeutics Shares Gaining Today?
Why Is Plus Therapeutics (PSTV) Stock Up 38% Today?
Plus Therapeutics Announces Share Repurchase Program
Plus Therapeutics GAAP EPS of -$0.19 misses by $0.01
Plus Therapeutics Q1 2022 Earnings Preview
See More Headlines
Receive PSTV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Plus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PSTV Company Calendar

Last Earnings
7/21/2022
Today
9/28/2022
Next Earnings (Estimated)
10/20/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PSTV
Employees
14
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.50
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+607.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-13,400,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$300,000.00
Book Value
$0.70 per share

Miscellaneous

Free Float
22,092,000
Market Cap
$11.19 million
Optionable
Not Optionable
Beta
0.11

Key Executives

  • Dr. Marc H. Hedrick M.D.Dr. Marc H. Hedrick M.D. (Age 59)
    Pres, CEO & Director
    Comp: $894.08k
  • Mr. Andrew J. Sims (Age 48)
    VP & CFO
    Comp: $377.13k
  • Dr. Norman D. LaFrance FACNP (Age 74)
    FACP, M.D., Chief Medical Officer & Sr. VP
    Comp: $459.98k
  • Ms. Desiree Smith (Age 58)
    Corp. Controller, Principal Financial & Accounting Officer
  • Dr. John K. Fraser (Age 61)
    Chief Scientist
  • Mr. Russ Havranek M.B.A.
    M.S., VP of Corp. Strategy, New Product Planning & Investor Relations
  • Mr. Gary S. Titus CPA (Age 62)
    Advisor













PSTV Stock - Frequently Asked Questions

Should I buy or sell Plus Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Plus Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PSTV shares.
View PSTV analyst ratings
or view top-rated stocks.

What is Plus Therapeutics' stock price forecast for 2022?

1 brokers have issued twelve-month price objectives for Plus Therapeutics' stock. Their PSTV share price forecasts range from $2.00 to $5.00. On average, they predict the company's stock price to reach $3.50 in the next year. This suggests a possible upside of 641.5% from the stock's current price.
View analysts price targets for PSTV
or view top-rated stocks among Wall Street analysts.

How have PSTV shares performed in 2022?

Plus Therapeutics' stock was trading at $1.05 on January 1st, 2022. Since then, PSTV stock has decreased by 55.0% and is now trading at $0.4720.
View the best growth stocks for 2022 here
.

When is Plus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 20th 2022.
View our PSTV earnings forecast
.

How were Plus Therapeutics' earnings last quarter?

Plus Therapeutics, Inc. (NASDAQ:PSTV) released its quarterly earnings data on Thursday, July, 21st. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by $0.06.

What other stocks do shareholders of Plus Therapeutics own?
What is Plus Therapeutics' stock symbol?

Plus Therapeutics trades on the NASDAQ under the ticker symbol "PSTV."

Who are Plus Therapeutics' major shareholders?

Plus Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Otter Creek Advisors LLC (1.47%) and Renaissance Technologies LLC (0.45%). Insiders that own company stock include Andrew John Hugh Macintyr Sims, Azeez Hayne, Greg Petersen, Howard Clowes, Marc H Hedrick, Marc H Hedrick and Robert P Lenk.
View institutional ownership trends
.

How do I buy shares of Plus Therapeutics?

Shares of PSTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Plus Therapeutics' stock price today?

One share of PSTV stock can currently be purchased for approximately $0.47.

How much money does Plus Therapeutics make?

Plus Therapeutics (NASDAQ:PSTV) has a market capitalization of $10.67 million and generates $300,000.00 in revenue each year. The company earns $-13,400,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis.

How can I contact Plus Therapeutics?

Plus Therapeutics' mailing address is 4200 MARATHON BLVD SUITE 200, AUSTIN TX, 78756. The official website for the company is www.plustherapeutics.com. The company can be reached via phone at 737-255-7194, via email at ir@plustherapeutics.com, or via fax at 858-450-4335.

This page (NASDAQ:PSTV) was last updated on 9/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.